Sunshine Guojian Pharmaceutical Shanghai Co Ltd
医疗健康 · 生物科技
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for the treatment of moderate to severe plaque psoriasis. The company was founded in 2002 and is based in Shanghai, China.
MARKET 市值 45.63B CNY PE 15.4x
52W ¥31.87 – ¥65.85
EODHD · Q 2026-03-31 · 同步 2026-07-14
QUALITY PEG — 营收 YoY 38.6%
▲ ROE 41.8% 营业利润率 44.0% 净利润率 68.9%
ANALYST 股息率 0.63%